Download PDF
Thromb Haemost 1983; 50(02): 610-619
DOI: 10.1055/s-0038-1665267
International Committee Communications
Schattauer GmbH Stuttgart

Platelet Function Inhibitors

Marian A Packham
The Department of Biochemistry, University of Toronto, Toronto, Ontario, Canada
› Author Affiliations
Further Information

Publication History

Received 28 April 1983

Accepted 10 May 1983

Publication Date:
18 July 2018 (online)

  PDF Download  Permissions and Reprints

Keywords

Platelet aggregation - Platelet inhibitors - Arachidonic acid - Cyclic AMP - Thromboxane synthetase
 

  • References

  • 1 Mustard JF, Packham MA, Kinlough-Rathbone RL. Mechanisms in thrombosis: Haemostasis and Thrombosis. Bloom AL, Thomas DP. (Eds) Churchill Livingstone; London: 1981. pp 503-526
    Google Scholar
  • 2 Fuster V, Chesebro JH. Antithrombotic therapy: Role of platelet- inhibitor drugs. I. Current concepts of thrombogenesis: role of platelets. Mayo Clinic Proc 1981; 56: 102-112
    PubMedGoogle Scholar
  • 3 Baumgartner HR, Muggli R, Tschopp TB, Turitto VT. Platelet adhesion, release and aggregation in flowing blood: effects of surface properties and platelet function. Thromb Haemostas 1976; 35: 124-138
    PubMedGoogle Scholar
  • 4 Groves HM, Kinlough-Rathbone RL, Richardson M, Jorgensen L, Moore S, Mustard JF. Thrombin generation and fibrin formation following injury to rabbit neointima: studies of vessel wall reactivity and platelet survival. Lab Invest 1982; 46: 605-612
    PubMedGoogle Scholar
  • 5 Packham MA, Kinlough-Rathbone RL, Reimers H-J, Scott S, Mustard JF. Mechanisms of platelet aggregation independent of adenosine diphosphate: Prostaglandins in Hematology. Silver MJ, Smith JB, Kocsis JJ. (Eds) Spectrum Publications; New York: 1977. pp 247-276
    Google Scholar
  • 6 Vargaftig BB, Chignard M, Benveniste J. Present concepts on the mechanisms of platelet aggregation. Biochem Pharmacol 1981; 30: 263-271
    CrossrefPubMedGoogle Scholar
  • 7 Charo IF, Feinman RD, Detwiler TC. Interrelationships of platelet aggregation and secretion. J Clin Invest 1977; 60: 866-873
    CrossrefPubMedGoogle Scholar
  • 8 Weiss HJ. Platelets. Pathophysiology and antiplatelet drug therapy. Alan R Liss; New York: 1982. pp 1-165
    Google Scholar
  • 9 Kinlough-Rathbone RL, Packham MA, Mustard JF. Platelet aggregation: Methods of Hematology. Measurements of Platelet Function. Harker LA, Zimmerman TS. (Eds) Churchill Livingstone; New York: (in press)
    Google Scholar
  • 10 Packham MA, Mustard JF. Normal and abnormal platelet activity: Blood Platelet Function: Hemodynamics and Medicinal Chemistry. Lasslo A. (Ed) Elsevier North Holland; New York: (in press)
    Google Scholar
  • 11 Kinlough-Rathbone RL, Packham MA, Reimers H-J, Cazenave JP, Mustard JF. Mechanisms of platelet shape change, aggregation, and release induced by collagen, thrombin, or A23187. J Lab Clin Med 1977; 90: 707-719
    PubMedGoogle Scholar
  • 12 Kinlough-Rathbone RL, Cazenave J-P, Packham MA, Mustard JF. Effect of inhibitors of the arachidonate pathway on the release of granule contents from rabbit platelets adherent to collagen. Lab Invest 1980; 42: 28-34
    PubMedGoogle Scholar
  • 13 Holmsen H. Platelet secretion (release reaction) - mechanism and pharmacology. Adv Pharmacol Therapeut 1978; 4: 97-109
    PubMedGoogle Scholar
  • 14 Feinstein MB, Walenga R. The role of calcium in platelet activation: Biochemistry of the Acute Allergic Reactions. Becker EL, Simon AS, Austen KF. (Eds) Alan R Liss; New York: 1981. pp 279-293
    Google Scholar
  • 15 Gerrard JM, White JG. Prostaglandins and thromboxanes: “Middlemen” modulating platelet function in hemostasis and thrombosis: Progress in Hemostasis and Thrombosis. Spaet TH. (Ed) Grune & Stratton; New York: 1978. 4 87-125
    Google Scholar
  • 16 Haslam RJ, Davidson MM L, Davies T, Lynham JA, McClenaghan MD. Regulation of blood platelet function by cyclic nucleotides. Adv Cyclic Nucl Res 1978; 9: 533-552
    PubMedGoogle Scholar
  • 17 Cazenave J-P, Dejana E, Kinlough-Rathbone RL, Richardson M, Packham MA, Mustard JF. Prostaglandins I2 and E1 reduce rabbit and human platelet adherence without inhibiting serotonin release from adherent platelets. Thromb Res 1979; 15: 273-279
    CrossrefPubMedGoogle Scholar
  • 18 Nachman RL, Leung LL K. Complex formation of platelet membrane glycoproteins IIb and IIIa with fibrinogen. J Clin Invest 1982; 69: 263-269
    CrossrefPubMedGoogle Scholar
  • 19 Packham MA, Mustard JF. Pharmacology of platelet-affecting drugs. Circulation 1980; 62 Suppl (Suppl. 05) 26-41
    PubMedGoogle Scholar
  • 20 Fuster V, Chesebro JH. Antithrombotic therapy: role of platelet inhibitor drugs. II. Pharmacologic effects of platelet-inhibitor drugs. Mayo Clin Proc 1981; 56: 185-195
    PubMedGoogle Scholar
  • 21 Rao GH R, Reddy KR, White JG. The influence of epinephrine on prostacyclin (PGI2) induced dissociation of ADP aggregated platelets. Prostaglandins Med 1980; 4: 385-397
    CrossrefPubMedGoogle Scholar
  • 22 Kinlough-Rathbone RL, Mustard JF, Perry DW, Dejana E, Cazenave J-P, Packham MA, Harfenist EJ. Factors influencing the deaggregation of human and rabbit platelets. Thromb Haemostas 1983; 49: 162-167
    PubMedGoogle Scholar
  • 23 Holmsen H. Platelet secretion: Hemostasis and Thrombosis. Basic Principles and Clinical Practice. Colman RW, Hirsh J, Marder VJ, Salzman EW. (Eds) J B Lippincott; Philadelphia: 1982: 390-403
    Google Scholar
  • 24 Holmsen H. Mechanisms of platelet secretion: Platelets: Cellular Response Mechanisms and their Biological Significance. Rotman A, Meyer FA, Gitler C, Silberberg A. (Eds) John Wiley & Son; New York: 1980. pp 249-263
    Google Scholar
  • 25 Vickers JD, Kinlough-Rathbone RL, Mustard JF. Changes in phosphatidylinositol-4,5-bisphosphate 10 seconds after stimulation of washed rabbit platelets with ADP. Blood 1982; 60: 1247-1250
    PubMedGoogle Scholar
  • 26 Rittenhouse-Simmons S. Production of diglyceride from phosphatidylinositol in activated human platelets. J Clin Invest 1979; 63: 580-587
    CrossrefPubMedGoogle Scholar
  • 27 Lapetina EG, Billah MM, Cuatrecasas P. The initial action of thrombin on platelets. Conversion of phosphatidylinositol to phosphatidic acid preceding the production of arachidonic acid J Biol Chem 1981; 256: 5037-5040
    PubMedGoogle Scholar
  • 28 Michell RH, Kirk CJ. The unknown meaning of receptor-stimulated inositol lipid metabolism. TIPS 1982; 3: 140-141
    PubMedGoogle Scholar
  • 29 Imai A, Yano K, Kameyama Y, Nozawa Y. Evidence for predominance of phospholipase A2 in release of arachidonic acid in thrombin-activated platelets. Phosphatidylinositol-specific phospholipase C may play a minor role in arachidonate liberation Jpn J Exp Med 1982; 52: 99-105
    PubMedGoogle Scholar
  • 30 Kishimoto A, Takai Y, Mori T, Kikkawa U, Nishizuka A. Activation of calcium and phospholipid-dependent protein kinase by diacylglycerol, its possible relation to phosphatidyl-inositol turnover. J Biol Chem 1980; 255: 2273-2276
    PubMedGoogle Scholar
  • 31 Gerrard JM, Peterson DA, White JG. Calcium mobilization: Platelets in Biology and Pathology 2. Gordon JL. (Ed) Elsevier/ North Holland; Oxford: 1981. pp 407-436
    Google Scholar
  • 32 Gerrard JM, Kindom SE, Peterson DA, Peller J, Krantz KE, White JG. Lysophosphatidic acids. Influence on platelet aggregation and intracellular calcium flux Am J Pathol 1979; 96: 423-438
    PubMedGoogle Scholar
  • 33 Lapetina EG. Regulation of arachidonic acid production: role of phospholipases C and A2 . TIPS 1982; 3: 116-119
    PubMedGoogle Scholar
  • 34 Winocour PD, Kinlough-Rathbone RL, Mustard JF. The effect of the phospholipase inhibitor mepacrine on platelet aggregation, the platelet release reaction and fibrinogen binding to the platelet surface. Thromb Haemostas 1981; 45: 257-262
    PubMedGoogle Scholar
  • 35 Bell RL, Kennedy DA, Stanford N, Majerus PW. Diglyceride lipase: A pathway for arachidonate release from human platelets. Proc Natl Acad Sci USA 1979; 76: 3238-3241
    CrossrefPubMedGoogle Scholar
  • 36 Chap H, Mauco G, Perret B, Plantavid M, Laffont F, Simon MF, Douste-Blazy L. Studies on topological distribution of arachidonic acid replacement in platelet phospholipids and on enzymes involved in the phospholipid effect accompanying platelet activation. Agents Actions 1981; 11: 538-540
    CrossrefPubMedGoogle Scholar
  • 37 Broeckman MJ, Ward JW, Marcus AJ. Fatty acid composition of phosphatidylinositol and phosphatidic acid in stimulated platelets. Persistence of arachidonyl-stearyl structure J Biol Chem 1981; 256: 8271-8274
    PubMedGoogle Scholar
  • 38 Rittenhouse-Simmons S. Changes in arachidonate-containing complex lipid during platelet stimulation. Thromb Haemostas 1981; 46: 321 (Abstr.)
    PubMedGoogle Scholar
  • 39 Seamon KB, Daly JW. Forskolin: a unique diterpene activator of cyclic AMP-generating systems. J Cyclic Nucleotide Res 1981; 7: 201-224
    PubMedGoogle Scholar
  • 40 Agarwal KC, Parks Jr RE. Inhibition of human platelet aggregation by forskolin, prostaglandin E1 and adenosine analogs. Fed Proc 1982; 41: 701
    PubMedGoogle Scholar
  • 41 Siegl AM, Daly JW, Smith JB. Inhibition of aggregation and stimulation of cyclic AMP generation in intact human platelets by the diterpene forskolin. Mol Pharmacol 1982; 21: 680-687
    PubMedGoogle Scholar
  • 42 Insel PA, Stengel D, Ferry N, Hanoune J. Regulation of adenylate cyclase of human platelet membranes by forskolin. J Biol Chem 1982; 257: 7485-7490
    PubMedGoogle Scholar
  • 43 Fleming JS, Buyniski JB. A potent new inhibitor of platelet aggregation and experimental thrombosis, anagrelide (BL-4162A). Thromb Res 1979; 15: 373-388
    CrossrefPubMedGoogle Scholar
  • 44 Smith JB. Effect of thromboxane synthetase inhibitors on platelet function: Enhancement by inhibition of phosphodiesterase. Thromb Res 1982; 28: 477-485
    CrossrefPubMedGoogle Scholar
  • 45 Beretz A, Cazenave J-P, Anton R. Inhibition of aggregation and secretion of human platelets by quercetin and other flavonoids: Structure-activity relationships. Agents Actions 1982; 12: 382-387
    CrossrefPubMedGoogle Scholar
  • 46 Beretz A, Stierlé A, Anton R, Cazenave J-P. Role of cyclic AMP in the inhibition of human platelet aggregation by quercetin, a flavonoid that potentiates the effect of prostacyclin. Biochem Pharmacol 1982; 31: 3597-3600
    CrossrefPubMedGoogle Scholar
  • 47 Hidaka H, Hayashi H, Kohri H, Kimura H, Hosokawa T, Igawa T, Saitoh Y. Selective inhibitor of platelet cyclic adenosine monophosphate phosphodiesterase, cilostamide, inhibits platelet aggregation. J Pharmacol Exp Ther 1979; 211: 26-30
    PubMedGoogle Scholar
  • 48 Coppe D, Sobel M, Seamans L, Levin F, Salzman EW. Preservation of platelet function and number by prostacyclin during cardiopulmonary bypass. J Thorac Cardiovasc Surg 1981; 81: 274-278
    PubMedGoogle Scholar
  • 49 Turney JH, Dodd NJ, Weston MJ. Prostacyclin in extracorporeal circulations. Lancet 1981; 1: 1101
    PubMedGoogle Scholar
  • 50 Groves HM, Kinlough-Rathbone RL, Cazenave J-P, Dejana E, Richardson M, Mustard JF. Effect of dipyridamole and prostacyclin on rabbit platelet adherence in vitro and vivo. J Lab Clin Med 1982; 99: 548-558
    PubMedGoogle Scholar
  • 51 Chesebro JH, Clements IP, Fuster V, Elveback LR, Smith HC, Bardsley WT, Frye RL, Holmes Jr DR, Vlietstra RE, Pluth JR, Wallace RB, Puga FJ, Orszulak TA, Piehler JM, Schaff HV, Danielson GK. A platelet-inhibitor-drug trial in coronary-artery bypass operations. N Engl J Med 1982; 307: 73-78
    CrossrefPubMedGoogle Scholar
  • 52 Burch JW, Stanford N, Majerus PW. Inhibition of platelet prostaglandin synthetase by oral aspirin. J Clin Invest 1978; 61: 314-319
    CrossrefPubMedGoogle Scholar
  • 53 Masotti G, Galanti G, Poggesi L, Abbate R, Neri SerneriG. Differential inhibition of prostacyclin production and platelet aggregation by aspirin. Lancet 1979; 2: 1213-1216
    PubMedGoogle Scholar
  • 54 Ellis EF, Wright KF, Jones PS, Richardson DW, Ellis CK. Effect of oral aspirin dose on platelet aggregation and vascular prostacyclin (PGI2) synthesis in humans and rabbits. J Cardiovasc Pharmacol 1980; 2: 387-397
    CrossrefPubMedGoogle Scholar
  • 55 Patrono C, Ciabattoni G, Pinca E, Pugliese F, Castrucci G, De Salvo A, Satta MA, Peskar BA. Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. Thromb Res 1980; 17: 317-327
    CrossrefPubMedGoogle Scholar
  • 56 Packham MA, Mustard JF. Pharmacology of antiplatelet agents and their role in coronary disease: Myocardial Infarction and Cardiac Death. Margulies E. (Ed) Academic Press; New York: 1983. pp 93-142
    Google Scholar
  • 57 Ah M, McDonald JW D. Interference by sulfinpyrazone and salicylate of aspirin inhibition of platelet cyclooxygenase activity. Prostaglandins Med 1979; 3: 327-332
    CrossrefPubMedGoogle Scholar
  • 58 Dejana E, Cerletti C, de Castellarnau C, Livio M, Galletti F, Latini R, de Gaetano G. Salicylate-aspirin interaction in the rat. Evidence that salicylate accumulating during aspirin administration may protect vascular prostacyclin from aspirin-induced inhibition J Clin Invest 1981; 68: 1108-1112
    CrossrefPubMedGoogle Scholar
  • 59 Vargaftig BB. The inhibition of cyclo-oxygenase of rabbit platelets by aspirin is prevented by salicylic acid and by phenanthrolines. Eur J Pharmacol 1978; 50: 231-241
    CrossrefPubMedGoogle Scholar
  • 60 Cerletti C, Livio M, de Gaetano G. Non-steroidal anti-inflammatory drugs react with two sites on platelet cyclo-oxygenase. Evidence from “in vivo” drug interaction studies in rats Biochim Biophys Acta 1981; 714: 122-128
    PubMedGoogle Scholar
  • 61 Peterson DA, Gerrard JM, Rao GH R, Mills EL, White JG. Interaction of arachidonic acid and heme iron in the synthesis of prostaglandins. Adv Prostaglandin Thrombox Res 1980; 6: 157-161
    PubMedGoogle Scholar
  • 62 Peterson DA, Gerrard JM, Rao GH R, White JG. Salicylic acid inhibition of the irreversible effect of acetylsalicylic acid on prostaglandin synthetase may be due to competition for the enzyme cationic binding site. Prostaglandins Med 1981; 6: 161-164
    CrossrefPubMedGoogle Scholar
  • 63 Livio M, Delmaschio A, Cerletti C, de Gaetano G. Indomethacin prevents the long-lasting inhibitory effect of aspirin on human platelet cyclo-oxygenase activity. Prostaglandins 1982; 23: 787-796
    CrossrefPubMedGoogle Scholar
  • 64 Butler KD, Dieterle W, Maguire ED, Pay GF, Wallis RB, White AM. Sustained effects of sulfinpyrazone: Cardiovascular Actions of Sulfinpyrazone: Basic and Clinical Research. McGregor M, Mustard JF, Oliver MF, Sherry S. (Eds) Symposia Specialists; Miami, Florida: 1980. pp 19-35
    Google Scholar
  • 65 Cazenave J-P, Kinlough-Rathbone RL, Packham MA, Mustard JF. The effect of acetylsalicylic acid and indomethacin on rabbit platelet adherence to collagen and the subendothelium in the presence of a low or high hematocrit. Thromb Res 1978; 13: 971-981
    CrossrefPubMedGoogle Scholar
  • 66 Gorman RR, Fitzpatrick FA, Miller OV. A selective thromboxane synthetase inhibitor blocks the cAMP lowering activity of PGH2 . Biochem Biophys Res Commun 1977; 79: 305-313
    CrossrefPubMedGoogle Scholar
  • 67 Needleman P, Raz A, Ferrendelli JA, Minkes M. Application of imidazole as a selective inhibitor of thromboxane synthetase in human platelets. Proc Natl Acad Sci USA 1977; 74: 1716-1720
    CrossrefPubMedGoogle Scholar
  • 68 Fitzpatrick FA, Gorman R, Bundy G, Honohan T, McGuire J, Sun F. 9,11-iminoepoxyprosta-5,13-dienoic acid is a selective thromboxane A2 synthetase inhibitor. Biochim Biophys Acta 1979; 573: 238-244
    CrossrefPubMedGoogle Scholar
  • 69 Allan G, Eakins KE, Kulkarni PS, Levi R. Inhibition of thromboxane A2 biosynthesis in human platelets by burimamide. Br J Pharmacol 1980; 71: 157-164
    CrossrefPubMedGoogle Scholar
  • 70 Smith JB, Jubiz W. OKY-1581: a selective inhibitor of thromboxane synthesis in vivo and in vitro. Prostaglandins 1981; 22: 353-363
    CrossrefPubMedGoogle Scholar
  • 71 Grimm LJ, Knapp DR, Senator D, Halushka PV. Inhibition of platelet thromboxane synthesis by 7-(l-imidazolyl) heptanoic acid: dissociation from inhibition of aggregation. Thromb Res 1981; 24: 307-317
    CrossrefPubMedGoogle Scholar
  • 72 Randall MJ, Parry MJ, Hawkeswood E, Cross PE, Dickinson RP. UK-37,248, a novel, selective thromboxane synthetase inhibitor with platelet anti-aggregatory and anti-thrombotic activity. Thromb Res 1981; 23: 145-162
    CrossrefPubMedGoogle Scholar
  • 73 Heptinstall S, Bevan J, Cockbill SR, Hanley SP, Parry MJ. Effects of a selective inhibitor of thromboxane synthetase on human blood platelet behaviour. Thromb Res 1980; 20: 219-230
    CrossrefPubMedGoogle Scholar
  • 74 Bertele V, Cerletti C, Schieppati A, Di Minno G, de Gaetano G. Inhibition of thromboxane synthetase does not necessarily prevent platelet aggregation. Lancet 1981; 1: 1057-1058
    PubMedGoogle Scholar
  • 75 Bertele V, Falanga A, Roncaglioni MC, Cerletti C, de Gaetano G. Thromboxane synthetase inhibition results in increased platelet sensitivity to prostacyclin. Thromb Haemostas 1982; 47: 294
    PubMedGoogle Scholar
  • 76 Vermylen J, Defreyn G, Carreras LO, Machin SJ, van Schaeren J, Verstraete M. Thromboxane synthetase inhibition as antithrombotic strategy. Lancet 1981; 1: 1073-1075
    PubMedGoogle Scholar
  • 77 Defreyn G, Deckmyn H, Vermylen J. A thromboxane synthetase inhibitor reorients endoperoxide metabolism in whole blood toward prostacyclin and prostaglandin E2 . Thromb Res 1982; 26: 389-400
    CrossrefPubMedGoogle Scholar
  • 78 Tremoli E, Maderna P, Colli S, Agradi E, Petroni A, Paoletti R. GYKI 14,451, a synthetic tripeptide inhibitor of thrombin: activity on platelet aggregation and arachidonic acid metabolism. Pharmacol Res Commun 1981; 13: 339-349
    CrossrefPubMedGoogle Scholar
  • 79 Collen D, Matsuo O, Stassen JM, Kettner C, Shaw E. In vivo studies of a synthetic inhibitor of thrombin. J Lab Clin Med 1982; 99: 76-83
    PubMedGoogle Scholar
  • 80 Barnathan ES, Addonizio VP, Shattil SJ. Interaction of verapamil with human platelet α-adrenergic receptors. Am J Physiol 1982; 242: H19-H23
    CrossrefPubMedGoogle Scholar
  • 81 Rossi EC, Louis G, Zeller EA. Structure activity relationships between catecholamines and the α-adrenergic receptor responsible for the aggregation of human platelets by epinephrine. J Lab Clin Med 1979; 93: 286-294
    PubMedGoogle Scholar
  • 82 Rao GH R, Johnson GJ, White JG. Influence of epinephrine on the aggregation response of aspirin-treated platelets. Prostaglandins Med 1980; 5: 45-58
    CrossrefPubMedGoogle Scholar
  • 83 Rao GH R, Gerrard JM, Witkop CJ, White JG. Platelet aggregation independent of ADP release or prostaglandin synthesis in patients with Hermansky-Pudlak syndrome. Prostaglandins Med 1981; 6: 459-472
    CrossrefPubMedGoogle Scholar
  • 84 Rao GH R, Reddy KR, White JG. Modification of human platelet response to sodium arachidonate by membrane modulation. Prostaglandins Med 1981; 6: 75-90
    CrossrefPubMedGoogle Scholar
  • 85 De Clerck F, David J-L, Janssen PA J. Inhibition of 5-hydroxytryptamine-induced and -amplified human platelet aggregation by ketan- serin (R 41 468), a selective 5-HT2-receptor antagonist. Agents Actions 1982; 12: 388-397
    CrossrefPubMedGoogle Scholar
  • 86 Aledort LM. Platelet aggregation: The Circulating Platelet. Johnson SA. (Ed) Academic Press; New York: 1971. pp 259-281
    Google Scholar
  • 87 Davies T, Davidson MM, McClenaghan MD, Say A, Haslam RJ. Factors affecting platelet cyclic GMP levels during aggregation induced by collagen and by arachidonic acid. Thromb Res 1976; 9: 387-405
    CrossrefPubMedGoogle Scholar
  • 88 Chignard M, Wal F, Lefort J, Vargaftig BB. Inhibition by sulphinpyrazone of the platelet-dependent bronchoconstriction due to platelet-activating factor (PAF-Acether) in the guinea-pig. Eur J Pharmacol 1982; 78: 71-79
    CrossrefPubMedGoogle Scholar
  • 89 Gasic GJ, Koch PA G, Hsu B, Gasic TB, Niewiarowski S. Thrombogenic activity of mouse and human tumors: effects on platelets, coagulation and fibrinolysis, and possible significance for metastases. Z Krebsforsch 1976; 86: 263-277
    CrossrefPubMedGoogle Scholar
  • 90 Jamieson GA, Scipio AR. (Eds) Interactions of platelets and tumor cells. Alan R Liss; New York: Prog Clin Biol Res. 1982. 89 1-523
    Google Scholar
  • 91 Donati MB, Rotillio D, Delaini F, Giavazzi R, Mantovani A, Poggi A. Animal models for the study of platelet-tumor cell interactions: Interaction of Platelets and Tumor Cells. Jamieson GA, Scipio AR. (Eds) Alan R Liss; New York: Prog Clin Biol Res. 1982. 89 159-176
    Google Scholar
  • 92 Langer BG, Leung LL K, Gonnella PA, Nachmias VT, Nachman RL, Pepe FA. α-Actinin and membrane glycoprotein Ilia are different proteins in human blood platelets. Proc Natl Acad Sci USA 1982; 79: 432-435
    CrossrefPubMedGoogle Scholar
  • 93 Niederman R, Pollard TD. Human platelet myosin. II. In vitro assembly and structure of myosin filaments. J Cell Biol 1975; 67: 72-92
    CrossrefPubMedGoogle Scholar
  • 94 Haslam RJ, Davidson MM, McClenaghan MD. Cytochalasin B, the blood platelet release reaction and cyclic GMP. Nature 1975; 253: 455-456
    CrossrefPubMedGoogle Scholar
  • 95 Kirkpatrick JP, Mclntire LV, Moake JL, Cimo PL. Differential effects of cytochalasin B on platelet release, aggregation and contractility: Evidence against a contractile mechanism for the release of platelet granular contents. Thromb Haemostas 1979; 42: 1483-1489
    PubMedGoogle Scholar
  • 96 Peerschke EI, Zucker MB. Relationship of ADP-induced fibrinogen binding to platelet shape change and aggregation elucidated by use of colchicine and cytochalasin B. Thromb Haemostas 1980; 43: 58-60
    PubMedGoogle Scholar
  • 97 Kuntamukkula MS, Moake JL, Mclntire LV, Cimo PL. Effects of colchicine and vinblastine on platelet contractility and release. Thromb Res 1982; 26: 329-339
    CrossrefPubMedGoogle Scholar
  • 98 Kindness G, Williamson FB, Long WF. Inhibitory effect of trifluoperazine on aggregation of human platelets. Thromb Res 1980; 17: 549-554
    CrossrefPubMedGoogle Scholar
  • 99 White II GC, Raynor ST. The effects of trifluoperazine, an inhibitor of calmodulin, on platelet function. Thromb Res 1980; 18: 279-284
    CrossrefPubMedGoogle Scholar
  • 100 Rao GH R, Reddy KR, White JG. Influence of trifluoperazine on platelet aggregation and disaggregation. Prostaglandins Med 1980; 5: 221-234
    CrossrefPubMedGoogle Scholar
  • 101 Mustard JF, Packham MA. Platelets, thrombosis and drugs: Cardiovascular Drugs. Vol. 3. Antithrombotic Drugs. Avery GS. (Ed) Adis Press; New York: 1978. 3 1-83
    Google Scholar
  • 102 Lips JP M, Sixma JJ, Schiphorst ME. The effect of ticlopidine administration to humans on the binding of adenosine diphosphate to blood platelets. Thromb Res 1980; 17: 19-27
    CrossrefPubMedGoogle Scholar
  • 103 Kirstein P, Jogestrand T, Johnsson H, Olsson AG. Antiaggregatory, physiological and clinical effects of ticlopidine in subjects with peripheral atherosclerosis. Atherosclerosis 1980; 36: 471-480
    CrossrefPubMedGoogle Scholar
  • 104 Conard J, Lecrubier C, Scarabin PY, Horellou MH, Samama M, Bousser MG. Effects of long term administration of ticlopidine on platelet function and hemostatic variables. Thromb Res 1980; 20: 143-148
    CrossrefPubMedGoogle Scholar
  • 105 Aukland A, Hurlow RA, George AJ, Stuart J. Platelet inhibition with ticlopidine in atherosclerotic intermittent claudication. J Clin Pathol 1982; 35: 740-743
    CrossrefPubMedGoogle Scholar
  • 106 Fiskerstrand C, Thompson I, Burnett E, Williams P, Anderton JL. Assessment of the effect of ticlopidine in arteriovenous access for haemodialysis. Haemostasis 1982; 12: 104
    PubMedGoogle Scholar
  • 107 Aubert O, Bernat A, Ferrand JC, Maffrand JP, Szygenda E, Tuong C, Vallee E. Pharmacological profile of PCR 3787: a metabolite of ticlopidine. Haemostasis 1982; 12: 137
    PubMedGoogle Scholar
  • 108 Cattaneo M, Kinlough-Rathbone RL, Winocour PD, Packham MA, Mustard JF. Ticlopidine prolongs shortened platelet survival by inhibiting clearance of altered platelets. Fed Proc 1982; 41: 701
    PubMedGoogle Scholar
  • 109 Kornecki E, Feinberg H. Pyridoxal phosphate inhibition of platelet function. Am J Physiol 1980; 238: H54-H60
    PubMedGoogle Scholar
  • 110 Lam SC-T, Harfenist EJ, Packham MA, Mustard JF. Investigation of possible mechanisms of pyridoxal 5’-phosphate inhibition of platelet reactions. Thromb Res 1980; 20: 633-645
    CrossrefPubMedGoogle Scholar
  • 111 Krishnamurthi S, Westwick J, Kakkar VV. Effect of pyridoxal 5’- phosphate (PALP) on human platelet aggregation, dense granule release and thromboxane B2 generation - role of Schiff base formation. Thromb Haemostas 1982; 48: 136-141
    PubMedGoogle Scholar
  • 112 Shattil SJ, McDonough M, Burch JW. Inhibition of platelet phospholipid methylation during platelet secretion. Blood 1981; 57: 537-544
    PubMedGoogle Scholar
  • 113 Randon J, Lecompte T, Chignard M, Siess W, Marlas G, Dray F, Vargaftig BB. Dissociation of platelet aggregation from transmethylation of their membrane phospholipids. Nature 1981; 293: 660-662
    CrossrefPubMedGoogle Scholar
  • 114 Lecompte T, Randon J, Chignard M, Vargaftig BB, Dray F. Interference of transmethylation inhibitors with thromboxane synthesis in rat platelets. Biochem Biophys Res Commun 1982; 106: 566-573
    CrossrefPubMedGoogle Scholar
  • 115 Baumgartner HR, Born GV R. The relation between the 5- hydroxytryptamine content and aggregation of rabbit platelets. J Physiol 1969; 201: 397-408
    CrossrefPubMedGoogle Scholar
  • 116 Hallam TJ, Scrutton MC, Wallis RB. Responses of rabbit platelets to adrenaline induced by other agonists. Thromb Res 1981; 21: 413-424
    CrossrefPubMedGoogle Scholar
  • 117 Holmes IB. Potentiating effect of adrenaline on adenosine diphosphate-induced reduction in rabbit circulating platelet count: inhibition by dihydroergotoxine. Thromb Haemostas 1979; 42: 641-648
    PubMedGoogle Scholar
  • 118 Doni MG, Aragno R. Effect of catecholamines on ADP aggregation of rat platelets in vivo. Experientia 1977; 33: 1331-1332
    CrossrefPubMedGoogle Scholar
  • 119 Markwardt F, Glusa E, Barthel W. Influence of dihydroergotoxine on platelet aggregation in rabbits. Thromb Res 1977; 10: 783-789
    CrossrefPubMedGoogle Scholar
  • 120 Huang EM, Detwiler TC. Characteristics of the synergistic actions of platelet agonists. Blood 1981; 57: 685-691
    PubMedGoogle Scholar
  • 121 Kinlough-Rathbone RL, Packham MA, Mustard JF. Synergism between platelet aggregating agents: the role of the arachidonate pathway. Thromb Res 1977; 11: 567-580
    CrossrefPubMedGoogle Scholar
  • 122 Groves HM, Kinlough-Rathbone RL, Mustard JF. Personal communication.
    PubMedGoogle Scholar
  • 123 Kallio V, Hamalainen H, Hakkila J, Luurila OJ. Reduction in sudden deaths by a multifactorial intervention programme after acute myocardial infarction. Lancet 1979; 2: 1091-1094
    PubMedGoogle Scholar
  • 124 Hjermann I, Byre KV, Holme I, Leren P. Effect of diet and smoking intervention on the incidence of coronary heart disease. Report of the Oslo Study Group of a randomised trial in healthy men Lancet 1981; 2: 1303-1313
    PubMedGoogle Scholar